Skip to content
Back
  • Home
  • About us
    • Management
    • Board
    • Team
    • Scientific advisory board
    • Partnerships
    • Investors
  • Our science
  • Pipeline
    • Pipeline
    • CP-012
    • CP-101
    • CP-102
    • CP-301
    • CP-107
    • CP-108
  • News
    • Press releases
  • Contact
    • Business Development
    • Social network
    • Career

Social
Network

See our social network

Stay Connected with Us on LinkedIn! Join our LinkedIn community for the latest updates and exciting company news.

Recent News

September 17, 2025
Contera Pharma announces positive topline results in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Hørsholm, September 17, 2025 - Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced positive topline…
Read more
August 28, 2025
Contera Pharma announces last patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal symptoms and morning akinesia in Parkinson’s disease
Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, today announced that the…
Read more

View all news

Contact us

Denmark map icon

Contera Pharma

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

Thomas Sager, CEO
info@conterapharma.com

 

Contact us

Contera Pharma

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

 

Thomas Sager, CEO

info@conterapharma.com

 

Connect on Linkedin

Useful links

About us

Our Science

Pipeline

News

Contact

Cookie policy

Privacy policy